Orthopedia Stock Price, News & Analysis

OrthoPediatrics Corp. (KIDS) reported a 9% year-over-year revenue increase for Q1 2022, generating $23.4 million compared to $21.5 million in Q1 2021. Domestic revenue grew by 8%, while international revenue rose by 13%. The company helped over 9,300 children during the quarter, reaching a total of more than 243,000 since inception. Gross profit improved by 14% to $18.6 million with a gross margin of 79.3%. Following the acquisition of MD Orthopaedics, full-year revenue guidance was raised to $122 million to $125 million.

OrthoPediatrics Corp. (NASDAQ: KIDS) plans to release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call to discuss these results will be held on May 5, 2022, at 8:00 a.m. ET, with dial-in numbers provided for domestic and international callers. The call will also be available via a live webcast on the company's investor relations page. Founded in 2006, OrthoPediatrics specializes in pediatric orthopedics, offering 37 surgical systems across trauma, scoliosis, and sports medicine sectors.

OrthoPediatrics (Nasdaq: KIDS) has been recognized with the Gold Award at the 2022 Medical Design Excellence Awards for its innovative ApiFix® System, which provides a less invasive surgical option for adolescent idiopathic scoliosis. The award highlights the system's patient benefits and market differentiation, assessed on design, healthcare benefits, and innovation. The ApiFix System was showcased at the 2022 International Meeting on Advanced Spine Techniques (IMAST) in Miami, reinforcing OrthoPediatrics’ commitment to pediatric orthopedic advancements.

OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its ApiFix® System has been selected as a finalist for the 2022 Medical Design Excellence Awards (MDEA). This recognition highlights the product's innovative approach to treating adolescent idiopathic scoliosis (AIS) without fusion. The MDEA evaluates entries based on design, function, benefits to healthcare, and market differentiation. The winners will be announced during MD&M West in Anaheim, CA, on April 12-14. OrthoPediatrics aims to enhance treatment options for pediatric patients with scoliosis.

OrthoPediatrics Corp. (Nasdaq: KIDS) announced its acquisition of MD Orthopaedics for up to $19.6 million, enhancing its portfolio with a patented solution for treating clubfoot. The deal includes an upfront payment of $8.2 million in cash and $8.9 million in stock, plus $2.5 million in restricted stock vesting over three years. MD Orthopaedics, known for its Ponseti Method bracing systems, has positively impacted 300,000 children globally. By integrating this technology, OrthoPediatrics aims to tap into a $600 million market and expand its reach in non-surgical pediatric orthopedic treatments.

OrthoPediatrics Corp (Nasdaq: KIDS) announced participation in the 21^st Annual Needham Virtual Healthcare Conference. Key executives, including President & CEO Dave Bailey, COO and CFO Fred Hite, and Executive Chairman Mark Throdahl, will engage in a fireside chat on April 12, 2022, at 12:45 PM ET. The event will be accessible via an audio webcast on the company’s investor relations website, with a replay available for 90 days post-event.

Founded in 2006, OrthoPediatrics focuses on pediatric orthopedic advancements, offering 36 surgical systems across trauma, scoliosis, and sports medicine.

OrthoPediatrics Corp. (Nasdaq: KIDS) has announced the limited launch of its innovative PediFlex™ Advanced Interlock Clamp System, enhancing pediatric orthopedic surgeries. This new technology addresses the issue of unwanted flexible nail migration in pediatric patients. The Interlock Clamps are compatible with intramedullary nails sized from 1.5mm to 4.5mm in stainless steel and titanium. The limited commercial launch in the U.S. will precede a global rollout later this year, demonstrating OrthoPediatrics' commitment to advancing pediatric orthopedic solutions.

OrthoPediatrics reported a 31% increase in Q4 2021 revenue, reaching $24.8 million. Full-year revenue reached $98.0 million, up 38% from 2020. Domestic revenue rose 24% while international jumped 150%. Despite an adjusted EBITDA loss of $0.2 million for 2021, it improved by $5.7 million from the prior year. The company guidance for 2022 anticipates revenue between $118 million and $121 million, with positive adjusted EBITDA expected. OrthoPediatrics helped over 38,000 children in 2021, showing strong market demand for its pediatric orthopedic products.

OrthoPediatrics Corp. (NASDAQ: KIDS) was the main sponsor of the 7th Annual International Children’s Spine Symposium held on February 25-26, 2022, in Orlando, Florida. The event featured lectures from renowned international experts and hands-on labs focused on pediatric spine issues. OrthoPediatrics showcased its innovative RESPONSE™ Scoliosis System and FIREFLY Pedicle Screw Navigation Guides. The company also highlighted its ApiFix System, a non-fusion alternative for scoliosis surgery, which is part of its expanding product line, originally acquired in 2020. OrthoPediatrics aims to enhance educational opportunities for pediatric orthopedic professionals.